Dermatofibrosarcoma protuberans with unusual sarcomatous transformation: A series of 4 cases with molecular confirmation

American Journal of Dermatopathology

Volumn 33, Issue 4, 2011, Pages 354-360

  Swaby, Michael G ^a   Evans, Harry L ^b   Fletcher, Christopher D M ^c   Prieto, Victor G ^b,d   Patel, Kayuri U ^e   Lev, Dina C ^b   Lòpez Terrada, Dolores ^e   Lazar, Alexander J F ^b,d   Wang, Wei Lien ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d University of Texas Health Science Center at Houston   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

COL1A1 PDGF ; dermatofibrosarcoma; fibrosarcomatous transformation; FISH; malignant fibrous histiocytoma; pleomorphism; RT PCR; undifferentiated pleomorphic sarcoma

Indexed keywords

CD34 ANTIBODY; COLLAGEN; COLLAGEN TYPE 1 ALPHA 1; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BACK; CASE REPORT; CELL PROLIFERATION; CHROMOSOME 17; CHROMOSOME 22; DERMATOFIBROSARCOMA PROTUBERANS; EXCISION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOREHEAD; GENE FUSION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOLECULAR DIAGNOSIS; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RING CHROMOSOME; SARCOMATOUS TRANSFORMATION; SCALP; SHOULDER; SPINDLE CELL; TUMOR CELL;

ADULT; ANTIGENS, CD34; CELL TRANSFORMATION, NEOPLASTIC; DERMATOFIBROSARCOMA; DNA, NEOPLASM; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 79958252173     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3182014631     Document Type: Article

References (22)

1. Weiss SW, Goldblum JR.Enzinger Weiss's Soft Tissue Tumor. 5th ed. St Louis, MO: Mosby Elsevier; 2008.
2. Mentzel T, Scharer L, Kazakov DV, et al. Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases. Am J Dermatopathol. 2007;29:443-448. (Pubitemid 47463852)
3. Terrier-Lacombe MJ, Guillou L, Maire G, et al. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data- a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2003;27:27-39. (Pubitemid 36014896)
4. Ding JA, Hashimoto H, Sugimoto T, et al. Bednar tumor (pigmented dermatofibrosarcoma protuberans). An analysis of six cases. Acta Pathol Jpn. 1990;40:744-754.
5. Connelly JH, Evans HL. Dermatofibrosarcoma protuberans. A clinicopathologic review with emphasis on fibrosarcomatous areas. Am J Surg Pathol. 1992;16:921-925.
6. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol. 2008;39: 184-193.
7. Llombart B, Sanmartin O, Lopez-Guerrero JA, et al. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1- PDGFB) study with therapeutic implications. Histopathology. 2009;54: 860-872.
8. Lemm D, Mugge LO, Mentzel T, et al. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol. 2009;135: 653-665.
9. Price VE, Fletcher JA, Zielenska M, et al. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer. 2005;44: 511-515. (Pubitemid 40614501)
10. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of plateletderived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002;20: 3586-3591. (Pubitemid 34983217)
11. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23:866-873. (Pubitemid 46224187)
12. McArthur GA. Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease. J Natl Compr Canc Netw. 2007;5: 557-562. (Pubitemid 46815216)
13. Lemm D,Muegge LO, Hoeffken K, et al. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans-a case report. Oral Maxillofac Surg. 2008;12:209-213.
14. Rutkowski P, Van Glabbeke M, Rankin CJ, et al.Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772-1779.
15. Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol. 2000;24:1125-1130. (Pubitemid 30612834)
16. Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous ("highgrade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol. 1998;22:576-587. (Pubitemid 28213745)
17. Abbott JJ, Oliveira AM, Nascimento AG. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol. 2006;30:436-443. (Pubitemid 43740143)
18. O'Dowd J, Laidler P. Progression of dermatofibrosarcoma protuberans to malignant fibrous histiocytoma: report of a case with implications for tumor histogenesis. Hum Pathol. 1988;19:368-370.
19. Szollosi Z, Scholtz B, Egervari K, et al. Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areas. J Clin Pathol. 2007;60:190-194.
20. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88:2711-2720. (Pubitemid 30417931)
21. Pizarro G, Fanburg J, Miettinen M. Dermatofibrosarcoma prouberans (DFSP) with fibrosarcomatous transformation: re-explored (Abstract). Mod Pathol. 1997;10:13A.
22. Abbott JJ, Erickson-Johnson M, Wang X, et al. Gains of COL1A1- PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mod Pathol. 2006;19: 1512-1518. (Pubitemid 44624172)